Title: Patel K, et al. ACTB-1003: An oral kinase inhibitor targeting cancer mutations (FGFR), angiogenesis (VEGFR2, TEK), and induction of apoptosis (RSK and p70S6K). Journal of Clinical Oncology 28, no. 15 DOI: 10.1200/jco.2010.28.15_suppl.e13665
942487-16-3 | Pf-03814735 | AA00GU2L | MFCD16659065
94226-20-7 | 2-Bromothieno[3,2-c]pyridine | AA00GU7D | MFCD17677030
877977-15-6 | 5-CYCLOPROPYL-4H-1,2,4-TRIAZOLE-3-THIOL | AA00GUAZ | MFCD07852054
923723-76-6 | 2-(Benzo[d]thiazol-2-yl)-2,2-dichloroacetonitrile | AA00GUEK | MFCD08691208
887350-95-0 | 2-Trifluoromethyl-5-nitrobenzonitrile | AA00GUNB | MFCD08448277
899897-21-3 | Methyl 5-bromo-2-methyl-1,3-thiazole-4-carboxylate | AA00GUUI | MFCD09265508
91969-74-3 | 4,5-Dimethyl-2-methoxyacetophenone | AA00GVAG | MFCD03789142
906075-26-1 | 1-Aminocycloheptanecarboxamide | AA00GVF4 | MFCD10686671
900711-15-1 | N-[3-(Acetylamino)phenyl]-3-chloropropanamide | AA00GVJP | MFCD01213667
90004-19-6 | 7-Methylpyrazolo[1,5-a]pyrimidine-6-carboxylic acid | AA00GVOK | MFCD11982988